NCT00425854 - An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

May 31, 2009

Conditions

Breast Neoplasms

Interventions

DRUG

BIBW 2992

high dose once daily

Trial Locations (14)

1200.10.3201 Boehringer Ingelheim Investigational Site, Brussels

1200.10.3208 Boehringer Ingelheim Investigational Site, Brussels

1200.10.3203 Boehringer Ingelheim Investigational Site, Charleroi

1200.10.3205 Boehringer Ingelheim Investigational Site, Ghent

1200.10.3204 Boehringer Ingelheim Investigational Site, Leuven

1200.10.3206 Boehringer Ingelheim Investigational Site, Wilrijk

1200.10.49005 Boehringer Ingelheim Investigational Site, Berlin

1200.10.49007 Boehringer Ingelheim Investigational Site, Düsseldorf

1200.10.49008 Boehringer Ingelheim Investigational Site, Erlangen

1200.10.49010 Boehringer Ingelheim Investigational Site, Essen

1200.10.49003 Boehringer Ingelheim Investigational Site, Kiel

1200.10.49004 Boehringer Ingelheim Investigational Site, Mainz

1200.10.49001 Boehringer Ingelheim Investigational Site, München

1200.10.49006 Boehringer Ingelheim Investigational Site, Wiesbaden